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Abstract
Aims To evaluate the cost-effectiveness of HypoAware, a blended (group and online) psycho-educational intervention
based on the evidence-based Blood Glucose Awareness Training, in comparison with usual care in people with Type 1
and Type 2 diabetes with a high risk of severe hypoglycaemia.
Methods We performed an economic evaluation, from a societal and healthcare perspective, that used data from a 6-
month, multicentre, cluster-randomized controlled trial (n = 137).
Results The proportion of people with at least one severe hypoglycaemic event per 6 months was 0.22 lower (95% CI –
0.39 to –0.06) and the proportion of people with impaired hypoglycaemia awareness was 0.16 lower (95% CI –0.34 to
0.02) in the HypoAware group. There was no difference in quality-adjusted life-years (–0.0; 95% CI –0.05 to 0.05). The
mean total societal costs in the HypoAware group were EUR708 higher than in the usual care group (95% CI –951 to
2298). The mean incremental cost per severe hypoglycaemic event prevented was EUR2,233. At a willingness-to-pay
threshold of EUR20,000 per event prevented, the probability that HypoAware was cost-effective in comparison with
usual care was 54% from a societal perspective and 55% from a healthcare perspective. For quality-adjusted life-years
the incremental cost-effectiveness ratio was EUR119,360/quality-adjusted life-year gained and the probability of cost-
effectiveness was low at all ceiling ratios.
Conclusions Based on the present study, we conclude that HypoAware is not cost-effective compared to usual care.
Further research in less well-resourced settings and more severely affected patients is warranted. (Clinical Trials Registry
no: Dutch Trial Register NTR4538.)
Diabet. Med. 35, 214–222 (2018)
Introduction
Severe hypoglycaemia is the major adverse event related
to insulin treatment in people with Type 1 diabetes and
people with insulin-treated Type 2 diabetes,. The estimated
average incidence of severe hypoglycaemia ranges from 1.0
to 1.7 events per patient per year. Most incidents occur in
people with Type 1 diabetes [1–3]. Longer disease duration
(>15 years) is associated with an increase in the incidence of
severe hypoglycaemia to 3.2 events per patient per year [4].
With progressive insulin deficiency, the frequency of severe
hypoglycaemic events in people with Type 2 diabetes is
similar to that in those with Type 1 diabetes because the
sulfonylurea or insulin treatment they receive increases the
risk of hypoglycaemia [5]. Hypoglycaemia causes significant
morbidity, reduced quality of life and increased mortality
[6–8], and leads to high societal costs. Severe hypoglycaemia-
related costs consist of increased healthcare utilizationCorrespondence to: Maartje de Wit. E-mail: m.dewit@vumc.nl
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(emergency room visits, ambulance costs, hospital admis-
sions, outpatient visits) and work absenteeism. It is estimated
that for each severe hypoglycaemic event requiring medical
assistance the healthcare costs are EUR2,100 and lost
productivity costs are EUR1,000 [6,9].
Psycho-educational interventions, such as Blood Glucose
Awareness Training (BGAT), aimed at reducing and
preventing hypoglycaemia, are evidence-based [10], but
demanding both on clinics’ resources as well as participants’
time as a result of the relatively high number of group
sessions and extensive homework assignments. To date, no
economic evaluations of BGAT-like programmes have been
conducted. Given the scarce resources available for health-
care, evidence that cost-effective interventions lower hypo-
glycaemia risk in diabetes is urgently needed. We therefore
developed a brief blended group intervention, HypoAware,
based on key ingredients of BGAT. We reduced the number
of group sessions to three 2.5-h sessions, combined with
an online learning environment to maintain quality and
improve attractiveness and comprehensibility, while keeping
resources (and thus costs) at a minimum. In a multicentre
pilot study of HypoAware in people with Type 1 and Type 2
diabetes and problematic hypoglycaemia, we demonstrated
feasibility and acceptability [11]. In addition, we conducted a
randomized controlled trial (RCT) and reported on the
clinical effectiveness, showing fewer severe hypoglycaemic
events, significantly improved hypoglycaemia awareness and
less hypo-distress compared with usual care [12].
In the present paper, we examined the cost-effectiveness of
the psycho-educational intervention HypoAware in people
with Type 1 and Type 2 diabetes who were at high risk of
hypoglycaemic events, and compared this with usual care,
from a societal and healthcare perspective. From the societal
perspective, all relevant costs were taken into account, that is
healthcare utilization, patient and lost productivity costs.
Although the societal perspective is recommended by the
Dutch National Healthcare Institute in view of healthcare
reimbursements [13], other national institutes such as the
National Institute for Clinical Excellence (NICE) recommend
a healthcare perspective, which only includes healthcare
utilization costs [14]. Quality-adjusted life-years (QALYs)
were included as an outcome measure next to the clinical
outcome measures of the trial, because decision-makers need
this information to be able to compare the cost-effectiveness
of HypoAware with other new interventions for diabetes or
other health conditions [15].
Participants and methods
An economic evaluation was performed from a societal and
healthcare perspective alongside a two-arm multicentre,
cluster-RCT with follow-up measurements at 2, 4 and
6 months conducted at eight self-selected outpatient diabetes
clinics in the Netherlands. The full design of the trial is
described elsewhere [16]. Cluster randomization was carried
out prior to recruitment of participants at the level of the
participating clinics to avoid contamination between treat-
ment groups within the clinics.
The study protocol was approved by the Ethics Committee
of the VU University Medical Centre, certified by the Central
Committee on Research involving Human Subjects in the
Netherlands (NL47354.029.13, registration number 2014.
007). We obtained written informed consent from all
participants.
Participants
In short, people were eligible for this study if they: were aged
≥18 years; were treated for Type 1 or Type 2 diabetes in an
outpatient setting; performed at least three insulin injections
a day or were on continuous subcutaneous insulin infusion;
and had a high risk of severe hypoglycaemia (one or more
severe hypoglycaemic events in the past 2 years and/or
impaired awareness of hypoglycaemia according to Gold
et al. (a score of ≥4) [17].
The main exclusion criteria were: serious medical comor-
bidity; major psychiatric disorder; pregnancy; insufficient
Dutch language skills; and visual impairment.
Intervention group: HypoAware
HypoAware consists of three group sessions of 2.5 h over a
period of 4 weeks, combined with two online modules in the
weeks between meetings. Groups are led by two trained
diabetes professionals and consist of eight participants.
HypoAware aims to improve symptom recognition and risk
awareness, provide preventive and problem-solving strate-
gies, and help the individual cope with (the risk of)
hypoglycaemia. More details can be found elsewhere [11].
Control group: usual care
Participants in the control group received usual care provided
by their diabetes team: a 10-min consultation with their
What’s new?
• We have evaluated the cost-effectiveness of HypoA-
ware, a blended (group and online) psycho-educational
intervention based on the evidence-based Blood Glu-
cose Awareness Training, in comparison with usual
care in people with diabetes with a high risk of severe
hypoglycaemia.
• HypoAware was not cost-effective from a societal
perspective in comparison with usual care. Further
research in less well-resourced settings and more
severely affected patients is warranted.
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endocrinologist every 3 to 6 months (depending on the
clinic’s protocol) and additional 45-min consultations with
their diabetes nurse, if needed. After the 6 month follow-up,
participants in the control group were offered HypoAware.
Outcomes
All measures were administered at the start, and 2, 4 and
6 months after baseline using web-based questionnaires.
Severe hypoglycaemic events were defined as those serious
enough to require the help of another person. We evaluated
the proportion of participants who had experienced one or
more severe hypoglycaemic event during the study period of
6 months. Whether those events needed medical assistance
was assessed using the TiC-P questionnaire (Trimbos/iMTA
questionnaire for costs associated with psychiatric illness; see
below).
We determined the proportion of participants with
impaired hypoglycaemia awareness using the one-item scale
proposed by Gold et al. [17]. A score of ≥4 indicates
impaired hypoglycaemia awareness. QALYs were estimated
using the EuroQoL five dimensions, five levels questionnaire
(EQ-5D-5L) as recommended by NICE [14,18]. The self-
reported EQ-5D-5L health states were converted to utility
scores using the Dutch EQ-5D-5L tariff [19]. QALYs were
subsequently calculated by multiplying the utility score
belonging to a health state by the time spent in that health
state. Changes in utility scores between two assessments were
linearly interpolated. QALYs were also calculated using the
participants’ ratings on the visual analogue scale included in
the EQ-5D-5L, using the methodology described above.
Costs were measured from a societal perspective using an
adapted version of the TiC-P questionnaire [20] with a recall
period of 2 months at 2, 4 and 6 months. Included were
costs of healthcare utilization (i.e. hospital admissions,
outpatient visits and calls, emergency room visits, ambulance
transfers, medication and medical supply usage), costs of
informal care, and lost productivity costs (reduced produc-
tivity from paid and unpaid work). When available, Dutch
guideline prices were used to value resource use (http://
www.zorginstituutnederland.nl). Medication use was valued
using Royal Dutch Society for Pharmacy prices [21]. Lost
productivity costs were calculated according to the friction
cost approach using sex-specific incomes of the Dutch
population [22]. According to the friction cost approach, a
sick employee is replaced after a certain amount of time
(friction period: 84 days in the Netherlands) after which
there are no more lost productivity costs. All costs were
adjusted to the year 2015 using consumer price indices.
Statistical analysis
Both cost-effectiveness and cost-utility analyses were
performed with a time horizon of 6 months; therefore,
discounting was not necessary. All analyses were intention-
to-treat. Missing cost and effect data were imputed using
multiple imputation with chained equations [23]. To account
for the skewed distribution of costs, predictive mean match-
ing was used in the multiple imputation with chained
equations procedure [24]. An imputation model was created
including variables that differed between groups at baseline,
baseline characteristics that were related to missingness of
cost and effect outcomes at 6 months follow-up, and baseline
characteristics that were associated with cost and effect
outcomes at 6-month follow-up (sex, age, nationality,
education, employment, marital status, comorbidity, dia-
betes duration, HbA1c, number of severe hypoglycaemic
events in the past 6 months and in the past 2 years, Gold
score, diabetes complications, diabetes treatment, and type
of diabetes). The number of imputed datasets was increased
until the loss of efficiency was lower than 5% [24]; in this
study, 20 imputed datasets were needed. The imputed
datasets were analysed separately as described below, and
subsequently results were pooled using Rubin’s rules [25].
Aggregated and disaggregated costs were calculated, and
95% CIs around cost differences were estimated using bias-
corrected accelerated bootstrapping (5000 replications) [26].
Bootstrapping was used because costs are generally heavily
skewed to the right.
In the cost-effectiveness analyses, cost and effect differ-
ences were estimated using seemingly unrelated regression.
The seemingly unrelated regression model consists of several
linear regression equations with different dependent and
explanatory variables, where the error terms in the different
regression equations are correlated [27]. Incremental cost-
effectiveness ratios (ICERs) were calculated by dividing the
difference in costs between the groups by the difference in
effects. Statistical uncertainty surrounding the ICERs was
estimated using bias-corrected accelerated bootstrapping
(5000 replications). Bootstrapped cost-effect pairs were
plotted in cost-effectiveness planes [28]. In a cost-effective-
ness plane, effect differences are plotted on the x-axis and
cost differences on the y-axis, resulting in four quadrants: the
northeast quadrant indicating that the HypoAware interven-
tion is more effective and associated with higher costs than
usual care; the southeast quadrant indicating that the
intervention is more effective and associated with lower
costs; the southwest quadrant indicating that the intervention
is less effective and associated with lower costs; and the
northwest quadrant indicating that the intervention is less
effective and associated with higher costs.
Cost-effectiveness acceptability curves show the probabil-
ity that the HypoAware intervention is cost-effective in
comparison with usual care (y-axis) at different ceiling ratios
(x-axis) [29]. The ceiling ratio is defined as the maximum
amount of money that society is willing to pay to gain one
unit of effect extra, e.g. one QALY gained or one severe
hypoglycaemic event prevented.
Two sensitivity analyses were performed. In the first
sensitivity analysis, analyses were performed from a
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healthcare perspective, meaning that only healthcare utiliza-
tion costs were taken into account. In the second sensitivity




Participants were recruited by their treating endocrinologist
or diabetes nurse. We have no records of the number of
participants invited. Baseline measurement was completed by
137 participants (Table 1): 66 participants (48%) in the
control group and 71 participants (52%) in the intervention
group. Full details of participant flow are described else-
where [12].
Clinical outcomes
Table 2 shows the clinical outcomes. Participants in the
intervention group reported, on average, 0.32 fewer events of
severe hypoglycaemia per 6 months than participants in the
usual care group (95% CI –5.4 to 4.8). The proportion of
participants with at least one event of severe hypoglycaemia
was 0.22 lower in the intervention group than in the control
group (95% CI –0.34 to –0.06). The proportion of partic-
ipants with impaired hypoglycaemia awareness was 0.16
lower in the intervention group (95% CI –0.34 to 0.02). The
mean number of QALYs based on the EQ-5D-5L dimensions
and thermometer did not differ between the two groups.
Costs
The mean total societal costs in the intervention group were
EUR708 higher than in the usual care group (95% CI –951
to 2,298; Table 2), but this difference was not statistically
significant. Healthcare costs were non-significantly lower in
the intervention group than in the usual care group (mean
difference: EUR–197, 95% CI –876 to 424).
The only costs that differed significantly between both
groups were diabetes costs (insulin, blood glucose test strips
and sensors), which were EUR348 lower in the HypoAware
group (95% CI –673 to –30), and costs of unpaid work (such
as cleaning, cooking, picking up children), which were EUR
1,094 higher in the HypoAware group (95% CI 529 to
1,876).
Cost-effectiveness
The ICER for the number of severe hypoglycaemic events
was EUR2,233/severe hypoglycaemic event prevented
(Table 3), meaning that to prevent one event of severe
hypoglycaemia 2,233 EUR should be invested in the
HypoAware group as compared with the usual-care group.
Forty percent of the bootstrapped ICERs were situated in the
north-east quadrant of the cost-effectiveness plane (Fig. 1a),
indicating that the intervention was, on average, more
effective in preventing severe hypoglycaemic events, but
was associated with higher costs than usual care. The cost-
effectiveness acceptability curve (Fig. 1b) shows that the
probability that the intervention was cost-effective in com-
parison with usual care was 0.24 at a willingness to pay of
EUR0 per severe hypoglycaemic event prevented, and that
this increases to a probability of 0.54 at a willingness to pay
of EUR20,000 per severe hypoglycaemic event prevented.
The probability of the intervention being cost-effective in
comparison with usual care in preventing one participant
having at least one severe hypoglycaemic event was 0.24 and
0.95 at willing-to-pay values of 0 and EUR15,000/hypogly-
caemic event prevented, respectively (Fig. 2a and b). For
hypoglycaemia unawareness, this probability was 0.24, 0.91
and 0.95 at willing-to-pay values of 0, EUR20,000 and
EUR84,000/participant with impaired awareness of hypo-
glycaemia prevented, respectively. Finally, for cost utility,
this probability was 0.24 and 0.27 at willing-to-pay values of
EUR0 and EUR20,000/QALY gained, respectively (Fig. 3a






Age, years 51.3 (14.0) 52.7 (12.4)
Female, n (%) 29 (44) 34 (48)
Employed, n (%) 37 (56) 37 (52)
Education, n (%)
Primary 16 (24) 23 (32)
Secondary 30 (46) 20 (28)
Higher 20 (30) 28 (39)
Type diabetes, n (%)
Type 1 diabetes 59 (91) 62 (87)
Type 2 diabetes 6 (9) 8 (11)
Other (MODY) 1 (2) 1 (1)
Treatment, n (%)
CSII 36 (55) 29 (41)
MDI 30 (46) 42 (59)
Comorbidity, n (%) 33 (50) 40 (56)
HbA1c, mmol/mol 60.4 (12.2) 60.8 (11.2)
HbA1c, % 7.7 (1.1) 7.7 (1.0)
Diabetes duration, years 27.5 (13.1) 24.6 (14.0)
Complications, n (%) 28 (42) 29 (41)
Non-severe hypoglycaemic events
per week (<4 mmol/l / <72 mg/dl)*
7.4 (3.9) 5.3 (3.8)
Impaired hypoglycaemia
awareness (Gold et al. [17]),
n (%)
48 (73) 56 (79)
Severe hypoglycaemic events in
the previous 6 months
1 (0–5) 2 (0–6)
Data are mean (SD) or median (interquartile range), unless
otherwise indicated.
CSII, continuous subcutaneous insulin infusion; MDI, multiple
daily injections; MODY, maturity onset diabetes of the young.
*In participants without real-time continuous glucose monitor-
ing at T1 (total n = 98; control n = 45; intervention n = 53).
Adapted from original article [12].
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and b). For QALYs based on the EQ-5D-5L thermometer,
these probabilities were similar (Table 3).
Sensitivity analyses
When only healthcare costs were taken into account, costs in
the intervention group were non-significantly lower than in
the usual care group (mean difference: – EUR197, 95% CI –
876 to 424), whereas societal costs were non-significantly
higher (Table 2). As compared to the main analysis, the
probabilities of HypoAware being cost-effective in compar-
ison with usual care were higher in this sensitivity analysis. In
particular, the cost-effectiveness acceptability curve shows
that the probability that the intervention was cost-effective in
comparison with usual care in preventing one severe hypo-
glycaemic event was 0.69 at a willingness to pay of EUR0/
severe hypoglycaemic event prevented and that this decreases
to a probability of 0.55 at a willingness to pay of
EUR20,000/severe hypoglycaemic event prevented (Table 3).
To prevent one participant having at least one severe
hypoglycaemic event, the probability of the intervention
being cost-effective in comparison with usual care was 0.69
and 0.95 at willing-to-pay values of 0 and EUR2,400/
hypoglycaemic event prevented, respectively. For hypogly-
caemia unawareness, this probability was 0.69 and 0.97 at
willing-to-pay values of 0 and EUR3,900/participant with
impaired hypoglycaemia awareness, respectively. Finally, for
cost utility, this probability was 0.69 and 0.60 at willing-to-
pay values of 0 and EUR20,000/QALY gained, respectively.
Sensitivity analyses among people with Type 1 diabetes
showed few differences compared with the total population
(Table 3). Societal costs were higher (mean difference:
EUR1,094, 95% CI –562 to 2749), but still non-significant.
Discussion
We conducted a multicentre trial to evaluate the cost-
effectiveness of HypoAware, a brief blended (online and
face-to-face) psycho-educational group intervention based on
BGAT in a sample of insulin-treated people with problematic
hypoglycaemia.
Total societal costs in the HypoAware group were
EUR708 higher than in the usual care group, but not
statistically significant. From a societal perspective, the
probability that the intervention was cost-effective in com-
parison with usual care was 0.54 at a willingness to pay of
EUR20,000/severe hypoglycaemic event prevented. For
QALYs, the maximum probability that HypoAware was
cost-effective in comparison with usual care was 0.27.
There was no significant difference between the interven-
tion and usual care groups in effects on severe hypoglycaemic
events, proportion of participants with impaired awareness
of hypoglycaemia and QALYs, but we did find a significant
difference in proportion of participants with at least one
event of severe hypoglycaemia. Improvement in events of
severe hypoglycaemia follows improvement in hypogly-
caemia awareness; this may translate into less severe hypo-
glycaemic events in the long term. From a healthcare
perspective, costs were lower in the HypoAware group
compared with the usual care group (EUR–197, 95% CI –
876 to 424), and the probability that the intervention was
cost-effective in comparison with usual care was 0.60 at a
willingness to pay of EUR20,000/QALY; however, when
interpreting the results of the study, one should take into
account that uncertainty is considerable, as shown by the
wide 95% CIs and the considerable spread of bootstrapped
cost-effect pairs in the cost-effectiveness plane. Also, the wide
Table 2 Mean outcomes and costs in 2015 Euros in both the HypoAware intervention and usual care groups, and mean differences (95% CIs)
between groups
Outcome HypoAware Mean (SE) Usual care Mean (SE) Difference (95% CI)
Clinical outcomes
Number of severe hypoglycaemic events 6.9 (2.1) 7.3 (1.4) 0.32 (–5.4; 4.8)
Proportion of participants with a severe hypoglycaemic events 0.59 (0.07) 0.81 (0.05) –0.22 (–0.39; –0.06)
Proportion of unaware participants 0.56 (0.07) 0.72 (0.06) –0.16 (–0.34; 0.02)
QALYs 0.34 (0.02) 0.34 (0.02) –0.00 (–0.05; 0.05)
QALY (visual analogue scale) 0.33 (0.01) 0.34 (0.01) –0.01 (–0.04; 0.02)
Costs, EUR, 2015
Healthcare costs 1896 (281) 2093 (297)
Primary care costs 328 (58) 209 (34) 119 (2; 242)
Secondary care costs 997 (204) 1138 (241) –141 (–715; 284)
Diabetes costs 398 (140) 746 (147) –348 (–673; –30)
Intervention costs 173 (0) NA NA
Informal care costs 427 (111) 437 (186) –9 (–623; 265)
Lost productivity costs 2459 (634) 1545 (382) 914 (–146; 2017)
Unpaid work 1532 (487) 438 (100) 1094 (529; 1876)
Absenteeism costs 499 (286) 881 (340) –383 (–1220; 153)
Presenteeism costs 428 (142) 225 (65) 203 (–17; 478)
Total societal costs 4783 (748) 4075 (625) 708 (–951; 2298)
NA, not applicable; QALY, quality-adjusted life year.
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95% CIs around costs (e.g. mean difference in total societal
costs EUR708, 95% CI –951 to 2,298) reflect the skewed
distribution of costs, meaning that much larger sample sizes
are needed to get a precise estimate than for clinical effects.
Sample size calculations in the present study were performed
for the main effectiveness analyses [30]. In addition, we did
not include a severely affected group in terms of hypogly-
caemia. This could also have affected the 95% CIs.
The difference in societal costs between the two groups
was mainly caused by the difference in costs of absenteeism
from unpaid work between the two groups. Although the
percentage of people with a paid job was slightly higher in
the usual care group (56%) than in the intervention group
(52%), we cannot adequately explain this difference in costs
between groups. The difference in diabetes costs is mainly a
result of higher use of real-time continuous glucose moni-
toring (CGM) in the control group. Real-time CGM use was
not an exclusion criterion in the present study because
standard Dutch diabetes care at the time of the study did not
include the use of real-time CGM for people at risk of
hypoglycaemia. The fact that the use of real-time CGM was
three times higher in the usual care group suggests that it was
used by participants to reduce problematic hypoglycaemia in
the absence of the HypoAware intervention. A recent study
demonstrated that real-time CGM is effective in lowering the
risk of hypoglycaemia in Type 1 diabetes [31], which has led
to accepting hypoglycaemia as an indication for reimburse-
ment. Comparing cost-effectiveness of HypoAware and real-
time CGM would be an interesting next step.
The differences observed between a societal and healthcare
perspective pose a dilemma. While the Dutch Care Institute
recommends analyses from a societal perspective to make
recommendations for reimbursements, NICE recommends
analyses from a healthcare perspective. One could argue that
when people are willing to pay for informal care and loss of
productivity costs themselves (in this case unpaid work), then
HypoAware would be more promising; however, this would
appear to require a political rather than a scientific discus-
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FIGURE 1 Number of severe hypoglycaemic events prevented. (a) Cost-
effectiveness plane: differences in effects between HypoAware and
usual care (x-axis) vs differences in costs between HypoAware and
usual care (y-axis). (b) Cost-effectiveness applicability curve: the
probability of cost-effectiveness of HypoAware in comparison with
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FIGURE 2 Proportion of participants with a severe hypoglycaemic
event prevented (a) Cost-effectiveness plane: differences in effects
between HypoAware and usual care (x-axis) vs differences in costs
between HypoAware and usual care (y-axis). (b) Cost-effectiveness
applicability curve: probability of cost-effectivess of HypoAware
in comparison with usual care (y-axis) at different ceiling ratios
(x-axis).
220 ª 2017 Diabetes UK
DIABETICMedicine Cost-effectiveness of HypoAware  M. de Wit et al.
The present study is the first to evaluate the cost-
effectiveness of a psycho-educational programme based on
BGAT; therefore, we cannot directly compare our results
with other studies. A recent study evaluated the cost-
effectiveness of a general psycho-educational training [Dose
Adjustment for Normal Eating (DAFNE)] in comparison
with no training for people with Type 1 diabetes from a
National Health Service perspective, and concluded that
there was a 54% probability that DAFNE was cost-
effective at a willingness to pay of GBP20,000 (approxi-
mately EUR22,000) per QALY [32]. In comparison, in the
present analysis we found, from the healthcare perspective,
a 60% probability at a willingness to pay of EUR20,000/
QALY.
The present study has some limitations. Firstly, for the
assessment of severe hypoglycaemic events we relied on self-
report. However, there is evidence that supports the reliability
of self-reported severe hypoglycaemia [33] and the use of
objective measures (glucose sensors) are costly. Secondly, a
follow-up period of 6 months is relatively short to
demonstrate a reduction in severe hypoglycaemic events and
associated costs, and longer-term research is therefore war-
ranted. Based on previous BGAT research and our own RCT,
however, we would expect the effects at 6 months to be
maintained until at least 1 year post intervention [10,12].
Thirdly, we used the EQ-5D-5L, a generic and non-event
related measure quality of life. This instrument has, however,
been shown to be valid and reliable [34], and a previous study
showed that fear of hypoglycaemia is adequately picked up by
the dimension ‘Anxiety/Depression’ [35]. Our QALY esti-
mates show that study participants experienced a substantial
decrease in quality of life (mean score 0.34 as compared with a
best possible score of 0.5); however, there was no substantial
difference (–0.001) in QALYs between the groups, despite the
higher number of hypoglycaemic events in the usual care
group as compared with the HypoAware group. This leads to
very large ICERs that are sensitive to the difference in costs.
Finally, while carers/partners of participants were invited to
the last group session of the HypoAware intervention, we did
not include them in the data collection and were thus not able
to assess the associated change in costs. This might be valuable
to add in future studies.
The strengths of the present study include the multicentre
cluster-randomized design, and the testing of the intervention
in a real-life setting in a representative sample, i.e. a mix of
people with Type 1 and Type 2 diabetes at risk of severe
hypoglycaemia. Moreover, costs were measured from a
societal and healthcare perspective, meaning that all relevant
costs were included and that shifts of costs between sectors
can be identified.
In conclusion, based on the results of this study, HypoA-
ware cannot be considered cost-effective from a societal
perspective. Further research in less well-resourced settings
and more severely affected patients is warranted.
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FIGURE 3 Quality-adjusted life-years. (a) Cost-effectiveness plane:
differences in effects between HypoAware and usual care (x-axis) vs
differences in costs between HypoAware and usual care (y-axis). (b)
Cost-effectiveness applicability curve: probability of cost utility of
HypoAware in comparison with usual care (y-axis) at different ceiling
ratios (x-axis). QALY, quality-adjusted life-year.
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